UNSPSC 51332104: Veralipride

This classification denotes an antipsychotic agent with the molecular formula C17H25N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7064109UD, chemically known as n-((1-allyl-2-pyrrolidinyl)methyl)-2,3-dimethoxy-5-sulfamoylbenzamid but generally known as veralipride, which bears US NIH Compound Identifier 47979. European Medicines Agency schedules Veralipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00037MIG.

UNSPSC 51332104 Veralipride is a Commodity code with minimal recent state and local procurement activity. The code nominally covers a single pharmaceutical product; however, recent opportunities tagged to this code show substantial mismatch with the product name. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems, the Texas Health and Human Services Commission issued an RFI regarding direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products through an RFP. None of these solicitations directly address veralipride or products named in the code, suggesting either a tagging error or that this UNSPSC code is not actively used by state and local procurement offices for meaningful commodity categorization. The issuing bodies include a county health department, a state health agency, and a multistate cooperative purchasing vehicle, indicating that when pharmaceutical procurement occurs at the state and local level, it typically routes through cooperative purchasing arrangements or large health system procurements rather than individual commodity codes.

Geographic activity spans Florida, Texas, and Minnesota based on recent postings, though the relevance of these opportunities to veralipride specifically is unclear. The Seminole County IFB (due July 26, 2023) sought naloxone and safe drug deactivation systems for quarterly delivery to the county community health building; the Texas HHS RFI (due April 3, 2026) explored direct-to-manufacturer prescription fulfillment models; and the MMCAP RFP (due March 26, 2026) required manufacturers to supply generic pharmaceuticals through authorized wholesalers with cGMP certification and DSCSA compliance. The code shows no dedicated activity and does not appear to be a working classification for state and local pharmaceutical procurement. Firms pursuing opportunities in pharmaceutical supply to state and local health agencies should monitor cooperative purchasing RFPs and state health department solicitations rather than track this code independently.